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Macular edema is one of the leading causes of visual
impairment in diabetic patients. An intravitreal anti-
vascular endothelial growth factor (anti-VEGF) agent is an
effective and crucial treatment. Systemic exposure to
these agents after intravitreal administration has been
discussed. However, decreasing renal function has scarcely
been reported.Case Report
A 67-year-old male with diabetes, hypertension, and
chronic kidney disease (CKD) suffered from persistently
blurred vision. His creatinine level in serum was 5.52 mg/dL
(glomerular filtration rateZ 11.1 mL/min/1.73m2), hemo-
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macular edema (DME) was diagnosed and his symptoms
improved after an intravitreal injection of 1.25 mg bev-
acizumab. The patient complained about blurred vision
again 1 year later and DME in his right eye was noted again.
His creatinine level was 8.81 mg/dL and BP was 182/
73 mmHg. Intravitreal injection of 0.5 mg ranibizumab was
performed after discussing the systemic risk with the
patient.
The patient had suffered from acute nausea since the
first postoperative day and went to the emergency room 4
days later. His BP was 164/72 mmHg but his creatinine level
increased to 12.09 mg/dL (Figure 1). Acute on CKD was
diagnosed. After emergent hemodialysis and the following
regular hemodialysis, his symptoms improved and macular
edema subsided for more than 6 months.
Discussion
VEGF is a vital factor which regulates glomerular vascular
permeability. Renal toxicity varying from proteinuria or
thrombotic microangiopathies to renal insufficiency have
been reported in patients receiving systemic anti-VEGF
therapy. Although the detailed mechanism causing renal
damage has not been clarified yet, disruption of theafter intravitreal antivascular endothelial growth factor therapy,
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Figure 1 The patient’s serum creatinine remained steady after intravitreal injection of 1.25 mg bevacizumab; his renal function
decreased gradually since March 2015. Four days after intravitreal injection of 0.5 mg ranibizumab, acute chronic kidney disease
was diagnosed and his serum creatinine dramatically increased to 12.09 mg/dL.
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+ MODELfiltration barrier and decrease in the expression of nephrin
have been suggested as two possible explanations for renal
toxicity after systemic anti-VEGF therapy.1 In addition,
thrombotic microangiography, focal segmental glomerulo-
sclerosis, and tubule-interstitial nephritis have been found
in pathology of the affected kidneys.2
Although the dosage of intravitreal anti-VEGF therapy is
w400 times lower than that of intravenous anti-VEGF
therapy, systemic exposure to these agents could be
observed in < 24 hours after intravitreal administration. It
has been estimated that the systemic concentration after
intravitreal injection of 1.25 mg bevacizumab, 0.5 mg
ranibizumab, and 2 mg aflibercept was 59.8e86.5 ng/mL,
0.2e2.36 ng/mL, and 20 ng/mL, with the half-life as 20
days, 2e6 hours, and 1.5 days, respectively. The concen-
tration of free plasma VEGF could be as low as 10 pg/mL
1 day after a single dose of intravitreal injection.3e7
There are only three patients (1 with macular degener-
ation and 2 with DME) who have been reported to be
suffering from acute renal injury after intravitreal anti-
VEGF therapy. Kidney biopsy in the former case showed
segmental duplications of glomerular basement membranes
with endothelial swelling, tubular atrophy, and noninflam-
matory interstitial fibrosis, recanalized arteriolar thrombi,
and fibrinogen deposits in the hilus of glomerulus.8 The
other two diabetic patients had preexisting Stage 4 CKD and
required long-term hemodialysis eventually.9 In the 2-year
results of a randomized trial conducted by the Diabetic
Retinopathy Clinical Research network, renal and urinary
disorders events were also been reported in 7e28% of
patients.10
Theoretically, bevacizumab has higher systemic con-
centration and longer half-life than ranibizumab. However,
the patient’s creatinine increased slowly after injection ofPlease cite this article in press as: Huang Y-F, et al., Acute renal failure
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two possible reasons for that. First, it might be caused by a
double-hit injury after two intravitreal injections, while
there was a 1-year interval between two treatments. Sec-
ond, the patient had Stage 5 CKD (glomerular filtration rate
< 15 mL/min/1.73m2) at the first presentation but even
less residual renal function when he received injection of
ranibizumab, which might lead to the acute chronic renal
failure episode. There was no other notable cause that
might coexist in this patient and would interact with the
effect of anti-VEGF in those postoperative days.
Although the possible clinical risk factors and dangerous
biomarkers for renal damage after anti-VEGF therapy have
not been clarified yet, our presenting case implicated that
ophthalmologists and internal medicine physicians should
pay additional attention and perform a complete frame-
work in performing this therapy for all patients, especially
for diabetic patients with preexisting CKD. In addition, this
is only a case report, and further collection of cases is
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